Safety and Efficacy of Etanercept in Patients With Psoriasis
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Anticipé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610083
- General Hospital of Chengdu Military Area Command PLA
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- has plaque psoriasis and has shown an unsatisfactory response to traditional DMARDs
- 18 to 75 years old
- has PGA of 3 or more at Day 0
- has BSA of 3% or more at Day 0
- has psoriasis severe enough to be eligible to systemic therapy
- willing to use an effective method of contraception for at least 30 days before Day 0 and until at least 1 month after the last drug administration;
- capable of giving informed consent
- with normal or non clinically significant chest X-ray within 6 months prior to Day 0
- with negative Purified Protein Derivative (PPD) or Quantiferon TB Gold test within 90 days prior to Day 0
- female patients of childbearing potential have a negative serum pregnancy test
- patient is able to start etanercept per the approved product monograph
Exclusion Criteria:
- has used topical steroids, topical tar preparations, or other anti-psoriatic preparations within the two weeks prior to Day 0 or during the study period
- has presence of erythrodermic, pustular or guttate psoriasis
- has had significant infections within the 30 days prior to Day 0
- has received investigational drugs within the four weeks prior to screening or during the study period
- has been treated with systemic anti-psoriatic drugs such as steroids, retinoids, cyclosporine, PUVA therapy or methotrexate within the four weeks prior to Day 0 or during the study period
- received systemic antibiotics within the four weeks prior to Day 0
- has been treated with ultraviolet light therapy (UVB, nbUVB) within the two weeks prior to Day 0 or during the study period
- has used infliximab within 14 days of Day 0 or during the study period
- has used other biologic agents for the treatment of psoriasis besides etanercept 8 weeks prior to Day 0 or during the study period
- has had an allergic reaction to infliximab
- has an unstable or serious medical condition as defined by the investigator or presence of any significant medical condition that might cause this study to be detrimental to the patient
- uncontrolled or severe comorbidities such as poorly controlled diabetes mellitus, NYHA class III or IV heart failure, history of myocardial infarction or cerebrovascular accident or transient ischemic attack within three months of screening visit; unstable angina pectoris
- uncontrolled hypertension, oxygen-dependent severe pulmonary disease
- has a known sero-positivity for HIV virus or history of any other immunosuppressive disease
- has active or chronic Hepatitis B or C
- has any mycobacterial disease, patient with a chest X-Ray suggestive of tuberculosis or patient taking anti-tuberculosis medication
- has a known hypersensitivity to etanercept or one of its components
- has received a live attenuated vaccine within the 12 weeks prior to Day 0 or plans to receive one during the study
- current pregnancy or lactation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Etanercept
Patients under the treatment of 50 mg Etanercept
|
|
|
Comparateur factice: Control
Patients under the treatment of traditional DMARDs
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Changes from baseline of Physician's Global Assessment (PGA) at 24 weeks
Délai: At 0 week, 12 weeks, 24 weeks
|
At 0 week, 12 weeks, 24 weeks
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Mean Body Surface Area (BSA)
Délai: At 0 week, 12 weeks, 24 weeks
|
At 0 week, 12 weeks, 24 weeks
|
|
Mean Psoriasis Area and Severity Index (PASI)
Délai: At 0 week, 12 weeks, 24 weeks
|
At 0 week, 12 weeks, 24 weeks
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement primaire
Achèvement de l'étude (Anticipé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies de la peau
- Maladies de la peau, papulosquameuses
- Psoriasis
- Effets physiologiques des médicaments
- Agents du système nerveux périphérique
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires non stéroïdiens
- Analgésiques, non narcotiques
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents gastro-intestinaux
- Étanercept
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- YSP20140688
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .